Navigation Links
Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in World's Largest Stent Registry
Date:9/2/2007

a from other TAXUS clinical trials and registries, offering further evidence that the TAXUS Liberte stent system continues to show positive safety outcomes in real-world use."

"The one-year OLYMPIA data show excellent outcomes with the TAXUS Liberte stent system across a large patient population with a broad range of lesion complexity, including diabetics who have typically demonstrated increased event rates," said Jeff Goodman, President of Boston Scientific International. "Our second-generation stent platform - TAXUS Liberte - offers exceptional deliverability and is the only current drug-eluting stent geometry designed specifically for drug elution. The strong clinical results, excellent performance in diabetics and solid physician preference have allowed TAXUS Liberte to take a clear leadership role in European and Intercontinental markets."

The global, prospective OLYMPIA registry is the world's largest DES registry and plans to enroll up to 26,000 patients from more than 400 centers worldwide. OLYMPIA is designed to analyze real-world clinical outcomes data for Boston Scientific's second-generation TAXUS Liberte paclitaxel-eluting stent system in the treatment of patients with coronary artery disease.

The OLYMPIA European and Intercontinental launch phases consisted of diverse and high-risk patient populations, reflecting complex usage patterns in "real-world" clinical practices. A majority of patients exhibited complex lesions or clinical characteristics, including, multi-vessel disease (57.7 percent), prior myocardial infarction (MI) (37.3 percent), acute MI (17.8 percent), multiple stents (32.9 percent), type B2/C lesions (56.6 percent) and diabetes (33.4 percent). Of the first 7,124 patients enrolled, 92.5 percent (6,593 patients) were available for evaluation at one year.

Patients with a single vessel treated with only one TAXUS Liberte stent were considered simple use patients and comprised 27.6 percent of the total. Complex use p
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Reforming FDA: Focus on safety, let market judge efficacy
2. Funds will support public safety communications interoperabilty
3. High interest forces delay in food safety symposium
4. Human factors and IT: Designing for patient safety
5. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
6. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
7. Thompson receives leadership award for technology solutions for patient safety
8. Thermal Cycling Profile for Standard PCR
9. PCR Polymerases Application Profiles
10. Setting up a kinase profiler with IMAP
11. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... December 11 Algeta ASA (OSE: ... first clinical center in the,US, the Tulane ... patients,in the phase III clinical study of ... hormone-refractory) prostate cancer,(CRPC) that has metastasized to ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) ...
(Date:12/10/2009)... Dec. 10 Dendreon Corporation (Nasdaq: DNDN ... public offering of 15,000,000 shares of its common stock ... share. Dendreon also granted to the underwriters a ... shares of common stock to cover overallotments, if any. ... 15, 2009, subject to customary closing conditions. ,, J. ...
(Date:12/10/2009)... -- Newly published research, by investigators, at ... (NESCI) in the journal STEM CELLS reported ... with "Limbal Stem Cell Deficiency" (LSCD) using ... need of suppressing their immunity. ,, ... a painful, blinding disease that requires long-term, ...
(Date:12/10/2009)... /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: ... developer and,producer of prescription drugs and licensed ... Republic of China ("PRC"), today reported that,effective ... operating entity of Lotus,appointed Mr. Jinzhong HAN ... Drug division ("OTC Division"). , ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3
... its strategy of digital convergence on Thursday at the Consumer ... home entertainment service. , ,Designed as part of the ... satellite TV, digital video recording and Internet service in a ... and DSL connection. , ,In his keynote address, SBC chairman ...
... , Milwaukee Johnson Controls plans ... company that will pay approximately 330 million Euros, or $430 ... France. Johnson Controls bought it in 2001 from another French ... 350 million Euros. , SBC Foundation donates $1 million to ...
... an experimental CIMSS satellite. Courtesy of UW-Madison. ... as the weather, the University of Wisconsin's Cooperative ... computer. , ,The institute has begun testing its weather ... offered by Silicon Graphics Inc. , a company ...
Other Biology Technology:SBC blends TV, video, music and the Internet in a new media box 2UW-Madison picks scalable SGI computer to simulate weather 2UW-Madison picks scalable SGI computer to simulate weather 3
(Date:12/11/2009)... PAAs consumer demand for premium fruit increases, growers ... to market. And to boost their bottom line, ... can increase fruit quality while reducing labor costs. ... growers to produce larger, healthier fruit, is among ... significant impact on fruit production overhead, and, ultimately, ...
(Date:12/11/2009)... University has granted an 18-month, exclusive option to ... insulin analogs. The company must reach certain milestones ... an exclusive license on therapies designed to help ... developing treatments that it hopes will become an ... insulin market. Insulin is a therapeutic protein used ...
(Date:12/11/2009)... December 11, 2009 Keystone Symposia on Molecular ... appointment of five new Keystone Symposia Fellows for ... five talented early-career life scientists (postdoctoral trainees or ... development process for one year. Fellows are selected ... a commitment to promoting diversity in the biomedical ...
Breaking Biology News(10 mins):Horizontal string trimmer reduces labor costs, increases peach size 2Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4Census Bureau to Announce Findings for Income Earnings Poverty and Health Insurance Coverage 56596 1Census Bureau to Announce Findings for Income Earnings Poverty and Health Insurance Coverage 56596 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 1Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 3Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 4Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 5Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 6Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 7Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 8Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 9PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16 2009 56592 1
... one of two teams in an international effort to ... to understand the role of individual genes in human ... School of Veterinary Science at the University of California, ... England. The National Institutes of Health (NIH), announced ...
... clinical trial evaluating new drug combinations for sleeping sickness, ... Medecins Sans Frontieres (MSF), and its research arm, Epicentre, ... Trials. , African trypanosomiasis, or sleeping sickness affects many tens ... and is a serious disease for which there are ...
... of countries and regions are transitioning from deforestation to ... world as a whole, according to researchers advancing a ... novel approach looks beyond simply how much of a ... volume of timber, biomass, and captured carbon within the ...
Other Biology News:Knockout Mouse Project 2End of deforestation in view? Experts advance new way to size up global forest resources 2End of deforestation in view? Experts advance new way to size up global forest resources 3End of deforestation in view? Experts advance new way to size up global forest resources 4End of deforestation in view? Experts advance new way to size up global forest resources 5End of deforestation in view? Experts advance new way to size up global forest resources 6
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: